Abstract
<p>Supplemental Figure 1. Validation of miR-214*, miR-124, miR-193a-3p, miR-485a-3p and miR-671-3p in independent sample set of tumor (ER+T and ER-T) and matching contralateral breast (ER+C, ER-C) compared to reduction mammoplasty controls. Supplemental Figure 2. Expression of ER in (A) CUB validation samples and (B) BBB samples. (A) There is no significant difference between ER+ CUB (ER+C) or ER- CUB (ER-C) and controls. Only the tumor samples (ER+T, ER-T) showed the significant difference vs controls. *** P<0.001. (B) there is no significant difference between ER+ BBB cases or ER- BBB cases and controls. Supplemental Table 1. Tumor characteristics three sample sets: Discovery set, validation set 1 and validation set 2. Supplemental Table 2. Differential expression of miRNAs between tumor (ER+ or ER-) and normal tissues from reduction mammoplasty. Supplemental Table 3. Correlation between miR-18a and other miRs and hormone receptor gene expression in validation samples. Supplemental Table 4. Correlation between miR-18a and miR-210 and hormone receptor gene expression in BBB samples. Supplemental Table 5. miR-18a Target Genes. Supplemental Table 6. miR-18a targets gene ontology by DAVID. Supplemental Table 7. miR-210 Target Genes. Supplemental Table 8. miR-210 targets gene ontology by DAVID.</p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
